Munich, 3-4 November 2016
#DareToShare
Career talks
Dr. Céline Carret
​
Scientific Editor at
EMBO Molecular Medicine
Céline Carret completed her PhD at the University of Montpellier, France, characterising host immunodominant antigens to fight babesiosis, a parasitic disease caused by a unicellular Apicomplexan parasite closely related to the malaria agent Plasmodium. She further developed her post-doctoral career, first in immunology working on CD45 and transgenic mice at The Babraham Institute, Cambridge, UK, then on malaria working at the Wellcome Trust Sanger Institute in Cambridge, UK and Instituto de Medicina Molecular in Lisbon, Portugal. Céline joined EMBO Molecular Medicine as a Scientific Editor in March 2011.
Dr. Silke Meiners
​
Group Leader at
Helmholtz Zentrum
Silke received her PhD from the Max Delbrück Center for Molecular Medicine in Berlin where she studied the role of morphogenetic factors in the metastasis of mammary carcinoma cells in the lab of Walter Birchmeier. She then went to the institute of Biochemistry, Charité in Berlin to complete her postdoctoral fellowship. In 1999 she became Assistant Professor in the Cardiovascular Research Lab in Berlin. Since 2010, Silke is a group leader in the Helmholtz Zentrum München where she works on the underlying structure and function relationship in the lung to have a more causal understanding of lung associated diseases.
Dr. Jonathan Stauber
​
CEO of Imabiotech
​
Jonathan received his PhD from the CNRS of Lille where he studied and developed MALDI Imaging used in Imaging Mass spectrometry in the lab of Michel Salzet and Isabelle Fournier. He worked also on the identification and the characterization of biomarkers in ovary cancer tissues and Parkinson Disease. He then went to the institute AMOLF where he worked on the development of Molecular mass spectrometry Imaging to define drug distribution and its effects in pathologies. In 2009 he became CSO and then CEO of Imabiotech, a Contract Research Organisation (CRO) which offers innovative imaging services to support drug efficacy and toxicity in preclinical and clinical stages.